Department of Pharmacy, Cleveland Clinic, Cleveland, Ohio.
Respiratory Institute, Cleveland Clinic, Cleveland, Ohio.
Pharmacotherapy. 2018 Mar;38(3):319-326. doi: 10.1002/phar.2082. Epub 2018 Feb 8.
Patients with septic shock often require vasoactive agents for hemodynamic support; however, the optimal approach to discontinuing these agents once patients reach the recovery phase is currently unknown. The objective of this evaluation was to compare the incidence of hypotension within 24 hours based on the discontinuation order of norepinephrine (NE) and vasopressin (AVP) in patients in the recovery phase of septic shock.
Retrospective cohort study.
The medical, surgical, and neurosciences intensive care units (ICUs) at a large tertiary care academic medical center.
A total of 585 adults in the recovery phase of septic shock who received fixed-dose AVP for at least 6 hours as an adjunct to NE between September 2011 and August 2015 were included. Of these patients, 155 had AVP discontinued first, and 430 had NE discontinued first.
Hypotension was evaluated during the 24-hour period after discontinuation of the first vasoactive agent and was defined as mean arterial pressure less than 60 mm Hg with one or more of the following interventions: increased remaining vasoactive agent dose by 25%, reinstitution of the discontinued agent, or administration of at least 1 L of fluid bolus. Time to hypotension was evaluated with survival analysis, and risk of hypotension was evaluated with multivariable Cox proportional hazards regression. No significant difference between groups was noted in the incidence of hypotension within 24 hours (55% in the AVP discontinued first group vs 50% in the NE discontinued first group, p=0.28) or ICU mortality (45.2% vs 40.0%, p=0.26). After adjustment for baseline factors with multivariable Cox proportional hazards regression, having AVP discontinued first was independently associated with an increased risk of hypotension with a time-varying effect that decreased over time (HR(t) = e , p<0.001).
In patients recovering from septic shock treated with concomitant AVP and NE, no significant difference was noted in the incidence of hypotension based on discontinuation order of these agents.
脓毒性休克患者常需使用血管活性药物进行血流动力学支持;然而,目前尚不清楚在患者进入复苏阶段时停止使用这些药物的最佳方法。本评估的目的是比较根据脓毒性休克复苏阶段患者去甲肾上腺素(NE)和血管加压素(AVP)停药顺序,在 24 小时内发生低血压的发生率。
回顾性队列研究。
一家大型三级保健学术医疗中心的内科、外科和神经科学重症监护病房(ICU)。
2011 年 9 月至 2015 年 8 月期间,共纳入 585 例接受固定剂量 AVP 治疗至少 6 小时作为 NE 辅助治疗的脓毒性休克复苏阶段的成年人。这些患者中,155 例先停用 AVP,430 例先停用 NE。
在停用第一种血管活性药物后的 24 小时内评估低血压,定义为平均动脉压<60mmHg,伴有以下一种或多种干预措施:增加剩余血管活性药物剂量 25%、重新使用已停用的药物或至少输注 1L 液体。用生存分析评估低血压的时间,用多变量 Cox 比例风险回归评估低血压的风险。两组在 24 小时内发生低血压的发生率(先停用 AVP 组为 55%,先停用 NE 组为 50%,p=0.28)或 ICU 死亡率(45.2%比 40.0%,p=0.26)无显著差异。在多变量 Cox 比例风险回归中调整基线因素后,先停用 AVP 与低血压风险增加相关,且随着时间的推移具有时变效应(HR(t) = e ,p<0.001)。
在接受 AVP 和 NE 联合治疗的脓毒性休克复苏患者中,根据这些药物的停药顺序,低血压的发生率无显著差异。